Welcome to our dedicated page for Danaher news (Ticker: DHR), a resource for investors and traders seeking the latest updates and insights on Danaher stock.
Danaher Corporation reports developments tied to its global life sciences and diagnostics businesses, where its companies provide scientific technologies, clinical diagnostic systems and tools used in discovery, diagnosis and therapy development. Recurring updates include earnings calls, dividend actions, investor conference appearances and product or regulatory milestones from operating businesses such as Beckman Coulter Diagnostics.
Company news also covers diagnostic assays, immunoassay analyzer platforms, clinical-laboratory workflows and the Danaher Business System, which the company uses as an operating framework across its businesses. Additional recurring themes include shareholder voting matters, governance updates and capital-structure disclosures.
Danaher Corporation (NYSE: DHR) has announced its upcoming quarterly earnings conference call for the fourth quarter of 2020, scheduled for January 28, 2021, at 8:00 a.m. ET. The call will last approximately one hour and will be available via webcast on Danaher's website. A replay will be accessible after the call until February 11, 2021. Additional related materials will be posted on the website at 6:00 a.m. ET on the call date.
Danaher Corporation (NYSE: DHR) announced the appointment of Dr. Jose-Carlos Gutierrez-Ramos as Senior Vice President and Chief Scientific Officer. Reporting directly to President and CEO Rainer M. Blair, Gutierrez-Ramos will lead Danaher’s science and technology strategy. A seasoned expert, he joins from Abbvie, where he was Head of Global Drug Discovery. His previous roles include leadership positions at Repertoire Immune Medicines and Pfizer, among others. Gutierrez-Ramos holds a Ph.D. in Immunology and extensive experience in academia and R&D.
Danaher Corporation (NYSE: DHR) appointed Jennifer L. Honeycutt as Executive Vice President, effective January 1, 2021. Honeycutt will oversee Beckman Coulter Life Sciences, Integrated DNA Technologies, and other key businesses. Previously, she served as Vice President and Group Executive for Pall and IDT in China, and President of Pall and Beckman Coulter. Her leadership is noted for driving growth within the Life Sciences platform. With 20 years at Danaher, she holds degrees in Chemistry and French, along with an MBA in Technology Management.
Danaher Corporation (NYSE: DHR) has declared a quarterly cash dividend of $0.18 per share for common stock, scheduled for payment on January 29, 2021 to shareholders of record as of December 28, 2020. Additionally, a dividend of $11.875 per share will be paid for its 4.75% Series A Mandatory Convertible Preferred Stock and $12.50 for the 5.00% Series B Mandatory Convertible Preferred Stock, both payable on January 15, 2021 to holders of record on December 31, 2020.
Danaher Corporation (NYSE: DHR) announced that President and CEO Rainer M. Blair will present at the Evercore ISI HealthCONx Conference on December 1, 2020, at 8:50 a.m. ET. The presentation will be available via audio webcast on www.danaher.com. Danaher is a global science and technology innovator focused on solving complex challenges in health care, environmental, and applied markets. The company operates over 20 businesses and employs more than 67,000 associates, united by the Danaher Business System and a mission to enhance quality of life worldwide.
Beckman Coulter has launched its Access SARS-CoV-2 IgG II assay, designed to measure antibody levels from past SARS-CoV-2 infections. This new assay allows clinicians to evaluate and track immune responses numerically, assisting in protective immunity research. The company is also filing for Emergency Use Authorization with the FDA and plans to ship the assay to U.S. customers. The assay boasts a high sensitivity (96.0%) and specificity (99.9%), and is compatible with existing workflows to enhance COVID-19 diagnostics.
Danaher Corporation (NYSE: DHR) announced that Executive Vice President and Chief Financial Officer, Matt McGrew, will present at the Wolfe Research Healthcare Conference on November 19, 2020, at 12:00 p.m. ET. The presentation will be available via simultaneous webcast on the Danaher website.
As a global innovator in science and technology, Danaher operates in healthcare, environmental, and applied markets, employing over 67,000 associates. For more information, visit www.danaher.com.
Summary not available.
Beckman Coulter has launched its Access SARS-CoV-2 Immunoglobulin M (IgM) assay in CE Mark countries. The test exhibits 99.9% specificity and 98.3% sensitivity 15-30 days post-symptom onset, offering a positive predictive value of 95.5% in populations with a 3% disease incidence. This assay complements Beckman Coulter's suite of COVID-19 testing solutions, which include IgG assays and an antigen test under development. Beckman Coulter aims to address high testing demands by leveraging its advanced automation technology, capable of delivering over 15 million tests monthly.
Cytiva has launched new services aimed at supporting point-of-care diagnostic developers, enhancing speed to market for new tests. The initiative includes establishing new labs in Germany and China, and expanding existing facilities in Wales. A multi-million dollar investment will boost diagnostic capabilities and supply chain enhancements. Cytiva has played a pivotal role during the COVID-19 pandemic, aiding the testing of over 50 million individuals. This investment is part of a broader $500 million plan to expand manufacturing capacity over five years.